Immunomedics (IMMU) Taps Greenhill & Co. as Strategic Advisor; Will Assist in IMMU-132 Out-Licensing

October 24, 2016 4:32 PM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Immunomedics, Inc. (Nasdaq: IMMU) announced that it has engaged Greenhill & Co., Inc. (NYSE: GHL) to serve as a strategic advisor primarily to assist in its ongoing efforts to out-license sacituzumab govitecan (IMMU-132), the Company’s lead investigational antibody-drug conjugate (ADC).

“The hiring of Greenhill is a testament of our commitment to complete a licensing arrangement for IMMU-132, as well as potentially other technology assets,” remarked Dr. David M. Goldenberg, Chairman, Chief Scientific Officer and Chief Patent Officer. “They will assist us in the review of our different partnering structures for IMMU-132,” he added.

The Company also announced the advisory services to the Chairman, provided by Dr. Sol J. Barer, have now ended. “I want to thank Sol for his contribution in strengthening our business and commercial development strategies, particularly in recommending Greenhill to us,” Dr. Goldenberg added.

Updated results with sacituzumab govitecan (IMMU-132) in patients with metastatic triple-negative breast cancer have been submitted for publication in a peer-reviewed medical journal. Presentations of results of sacituzumab govitecan in other indications are also planned.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment